Brent Ahrens joined Canaan in 1999 as a member of the Kauffman Fellows Program. A raconteur extraordinaire, in his work hours, Brent focuses on healthcare investments and has led investments in life sciences companies such as DexCom (DXCM), Revivant (acquired by ZOLL), Peninsula Pharmaceuticals (acquired by JNJ), Cerexa (acquired by FRX), Calixa (acquired by CBST), Durata Therapeutics (DRTX), and Elevation Pharmaceuticals (acquired by DNPUF). Brent serves on the board of Durata Therapeutics, a biopharmaceutical company pursuing late-stage clinical development of novel antibiotic programs. He is also on the boards of EndoGastric Solutions, the leading company offering medical devices for treatment of reflux disease; Minimally Invasive Devices, a developer of a franchise of products that substantially improve visualization during laparoscopic surgery; Relievant MedSystems, a maker of minimally invasive devices to relieve chronic back pain; Semnur Pharmaceuticals (acquired by Scilex Pharmaceuticals), a developer of pain managements solutions; and Spinifex, a biotech company developing new treatments for chronic pain.
Prior to joining Canaan, Brent worked in both commercial and technical roles at General Surgical Innovations, Ethicon Endo-Surgery (J&J), and IAP Research. He also has several surgical instrument patents to his credit. Brent earned an MBA from the Tuck School of Business at Dartmouth College after graduating with a B.S. and M.S. in Mechanical Engineering from the University of Dayton.